Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M A Pfeffer

Showing results (171-180 of 188) with videos related to

Pageof 19
Sort By:
American Heart Journal|October 31, 2000
Valsartan in acute myocardial infarction trial (VALIANT): rationale and designM A Pfeffer, J McMurray, A Leizorovicz, et al.
The American Journal of Medicine|October 24, 2000
Sex-related differences in the use and adverse effects of angiotensin-converting enzyme inhibitors in heart failure: the study of patients intolerant of converting enzyme inhibitors registryM R Shah, C B Granger, B A Bart, et al.
The New England Journal of Medicine|April 18, 1996
Absence of association or genetic linkage between the angiotensin-converting-enzyme gene and left ventricular massK Lindpaintner, M Lee, M G Larson, et al.
Annals of Internal Medicine|December 5, 1998
Effect of pravastatin on cardiovascular events in older patients with myocardial infarction and cholesterol levels in the average range. Results of the Cholesterol and Recurrent Events (CARE) trialS J Lewis, L A Moye, F M Sacks, et al.
Journal of the American College of Cardiology|February 6, 1999
Influence of baseline lipids on effectiveness of pravastatin in the CARE Trial. Cholesterol And Recurrent EventsM A Pfeffer, F M Sacks, L A Moyé, et al.
Circulation|January 20, 1999
Reduction of stroke incidence after myocardial infarction with pravastatin: the Cholesterol and Recurrent Events (CARE) study. The Care InvestigatorsJ F Plehn, B R Davis, F M Sacks, et al.
Clinical Journal of the American Society of Nephrology : CJASN|March 31, 2023
Influence of albuminuria on cardiovascular risk in patients with stable coronary artery disease. Circulation 116: 2687-2693, 2007S D Solomon, J Lin, C G Solomon, et al.
The New England Journal of Medicine|October 3, 1996
The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigatorsF M Sacks, M A Pfeffer, L A Moye, et al.
Circulation|June 17, 1997
Early versus delayed angiotensin-converting enzyme inhibition therapy in acute myocardial infarction. The healing and early afterload reducing therapy trialM A Pfeffer, S C Greaves, J M Arnold, et al.
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|March 4, 2017
Filtration Markers, Cardiovascular Disease, Mortality, and Kidney Outcomes in Stable Kidney Transplant Recipients: The FAVORIT TrialM C Foster, D E Weiner, A G Bostom, et al.
Pageof 19

Showing results (171-180 of 188) with videos related to

Sort By:
Pageof 19
American Heart Journal|October 31, 2000
Valsartan in acute myocardial infarction trial (VALIANT): rationale and designM A Pfeffer, J McMurray, A Leizorovicz, et al.
The American Journal of Medicine|October 24, 2000
Sex-related differences in the use and adverse effects of angiotensin-converting enzyme inhibitors in heart failure: the study of patients intolerant of converting enzyme inhibitors registryM R Shah, C B Granger, B A Bart, et al.
The New England Journal of Medicine|April 18, 1996
Absence of association or genetic linkage between the angiotensin-converting-enzyme gene and left ventricular massK Lindpaintner, M Lee, M G Larson, et al.
Annals of Internal Medicine|December 5, 1998
Effect of pravastatin on cardiovascular events in older patients with myocardial infarction and cholesterol levels in the average range. Results of the Cholesterol and Recurrent Events (CARE) trialS J Lewis, L A Moye, F M Sacks, et al.
Journal of the American College of Cardiology|February 6, 1999
Influence of baseline lipids on effectiveness of pravastatin in the CARE Trial. Cholesterol And Recurrent EventsM A Pfeffer, F M Sacks, L A Moyé, et al.
Circulation|January 20, 1999
Reduction of stroke incidence after myocardial infarction with pravastatin: the Cholesterol and Recurrent Events (CARE) study. The Care InvestigatorsJ F Plehn, B R Davis, F M Sacks, et al.
Clinical Journal of the American Society of Nephrology : CJASN|March 31, 2023
Influence of albuminuria on cardiovascular risk in patients with stable coronary artery disease. Circulation 116: 2687-2693, 2007S D Solomon, J Lin, C G Solomon, et al.
The New England Journal of Medicine|October 3, 1996
The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigatorsF M Sacks, M A Pfeffer, L A Moye, et al.
Circulation|June 17, 1997
Early versus delayed angiotensin-converting enzyme inhibition therapy in acute myocardial infarction. The healing and early afterload reducing therapy trialM A Pfeffer, S C Greaves, J M Arnold, et al.
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|March 4, 2017
Filtration Markers, Cardiovascular Disease, Mortality, and Kidney Outcomes in Stable Kidney Transplant Recipients: The FAVORIT TrialM C Foster, D E Weiner, A G Bostom, et al.
Pageof 19